Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5102 Target Snapshot

Transient receptor potential cation channel subfamily V member 1 · SINGLE PROTEIN · Rattus norvegicus

1,774Compounds
340Assays
4Approved Drugs
3,081.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt O35433. Use UniProt O35433 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt O35433 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Transient receptor potential cation channel subfamily V member 1 as ChEMBL target CHEMBL5102, mapped to UniProt O35433. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Transient receptor potential cation channel subfamily V member 1
SINGLE PROTEIN · Rattus norvegicus
As of 2026-09-13
ChEMBL target ID
CHEMBL5102
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O35433
Transient receptor potential cation channel subfamily V member 1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Transient receptor potential cation channel subfamily V member 1 is the right protein anchor across sources, using UniProt O35433 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelTransient receptor potential cation channel subfamily V member 1
UniProt AccessionO35433
Component TypeProtein
Sequence Length838 aa

Transient receptor potential cation channel subfamily V member 1

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Transient receptor potential cation channel subfamily V member 1, mapped to UniProt O35433. Sequence length is 838 aa.

Mapped IDO35433
Review nameTransient receptor potential cation channel subfamily V member 1
OrganismRattus norvegicus
Clinical Profile

Clinical Phase Distribution

4
Approved
5
Phase III
8
Phase II
1
Phase I
Assay Mix

Activity Type Distribution

IC501,895.0
KI844.0
EC50341.0
KD1.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL17976 10.7 Ki 0.02 Clinical
CHEMBL2414497 10.3 IC50 0.05 Preclinical
CHEMBL104647 10.27 Ki 0.054 Preclinical
CHEMBL4060041 10.19 Kd 0.064 Preclinical
CHEMBL455580 10.16 IC50 0.069 Preclinical
CHEMBL504725 10.14 Ki 0.073 Preclinical
CHEMBL3689037 10.0 Ki 0.1 Preclinical
CHEMBL3689046 10.0 Ki 0.1 Preclinical
CHEMBL4125690 10.0 Ki 0.1 Preclinical
CHEMBL6042549 10.0 IC50 0.1 Preclinical
Distribution

pChEMBL Value Distribution

138
5.0
287
5.5
421
6.0
472
6.5
430
7.0
253
7.5
205
8.0
114
8.5
78
9.0
21
9.5
pChEMBL
Approved Drugs

Approved Drugs

CAPSAICIN
CHEMBL294199
Approved 2009
CHLORPROMAZINE
CHEMBL71
Approved 1957
Assay Landscape

Assay Landscape

340
Total Assays
1,312
Tested Compounds
2
Assay Types
Binding — 194 assays, 1,312 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 138 772 6.8
single protein format 36 134 7.2
assay format 10 378 6.5
tissue-based format 6 15 8.0
cell membrane format 4 13 6.6
Functional — 146 assays, 798 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 113 658 7.2
assay format 19 113 6.8
tissue-based format 10 27 6.5
organism-based format 4 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine